Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors.

IF 9.2 1区生物学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

npj Biofilms and Microbiomes Pub Date : 2025-09-02 DOI:10.1038/s41522-025-00819-2

Lihaoyun Huang, Yu Li, Chunyan Zhang, Aimin Jiang, Lingxuan Zhu, Weiming Mou, Kailai Li, Jian Zhang, Cui Cui, Xinfang Cui, Anqi Lin, Peng Luo, Ting Wei

{"title":"Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors.","authors":"Lihaoyun Huang, Yu Li, Chunyan Zhang, Aimin Jiang, Lingxuan Zhu, Weiming Mou, Kailai Li, Jian Zhang, Cui Cui, Xinfang Cui, Anqi Lin, Peng Luo, Ting Wei","doi":"10.1038/s41522-025-00819-2","DOIUrl":null,"url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, with the microbiome significantly influencing treatment outcomes. Analysis of 4663 studies (2014.01-2024.10) identified 71 eligible randomized controlled trials (RCTs) and cohort studies (41 viral, 30 bacterial). Analyses included subgroup assessments by cancer type, microbial taxa, and ICI regimens. Among 4663 identified studies, 71 met inclusion criteria (41 viral, 30 bacterial). Viral status, particularly hepatitis B virus (HBV) and human papillomavirus (HPV), significantly associated with ORR and DCR. Bacterial enrichment correlated with improved survival in hepatobiliary (OS: HR = 4.33, 95%CI: 2.20-8.50) and lung cancers (PFS: HR = 1.70, 95%CI: 1.04-2.78). Multi-microbiome models demonstrated superior outcome prediction, with microbial diversity correlating with improved PFS (HR = 0.64, 95%CI: 0.42-0.98). Viral status showed cancer-specific associations with SAEs. The microbiome serves as a valuable predictor of ICI outcomes. Future studies should emphasize large-scale RCTs, standardized assessment methods, and host-microbiome interactions.</p>","PeriodicalId":19370,"journal":{"name":"npj Biofilms and Microbiomes","volume":"11 1","pages":"180"},"PeriodicalIF":9.2000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12405452/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"npj Biofilms and Microbiomes","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1038/s41522-025-00819-2","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, with the microbiome significantly influencing treatment outcomes. Analysis of 4663 studies (2014.01-2024.10) identified 71 eligible randomized controlled trials (RCTs) and cohort studies (41 viral, 30 bacterial). Analyses included subgroup assessments by cancer type, microbial taxa, and ICI regimens. Among 4663 identified studies, 71 met inclusion criteria (41 viral, 30 bacterial). Viral status, particularly hepatitis B virus (HBV) and human papillomavirus (HPV), significantly associated with ORR and DCR. Bacterial enrichment correlated with improved survival in hepatobiliary (OS: HR = 4.33, 95%CI: 2.20-8.50) and lung cancers (PFS: HR = 1.70, 95%CI: 1.04-2.78). Multi-microbiome models demonstrated superior outcome prediction, with microbial diversity correlating with improved PFS (HR = 0.64, 95%CI: 0.42-0.98). Viral status showed cancer-specific associations with SAEs. The microbiome serves as a valuable predictor of ICI outcomes. Future studies should emphasize large-scale RCTs, standardized assessment methods, and host-microbiome interactions.

Abstract Image

查看原文本刊更多论文

微生物组与免疫疗法：解开免疫检查点抑制剂的隐藏预测因子。

免疫检查点抑制剂（ICIs）已经彻底改变了癌症免疫治疗，微生物组显著影响治疗结果。对4663项研究（2014.01-2024.10）的分析确定了71项符合条件的随机对照试验（rct）和队列研究（41项病毒研究，30项细菌研究）。分析包括根据癌症类型、微生物分类群和ICI方案进行的亚组评估。在鉴定的4663项研究中，71项符合纳入标准（41项病毒研究，30项细菌研究）。病毒状态，特别是乙型肝炎病毒（HBV）和人乳头瘤病毒（HPV），与ORR和DCR显著相关。细菌富集与改善肝胆癌（OS: HR = 4.33, 95%CI: 2.20-8.50）和肺癌（PFS: HR = 1.70, 95%CI: 1.04-2.78）的生存率相关。多微生物组模型显示出更好的预后预测，微生物多样性与改善的PFS相关（HR = 0.64, 95%CI: 0.42-0.98）。病毒状态显示与SAEs有癌症特异性关联。微生物组是ICI结果的一个有价值的预测指标。未来的研究应强调大规模随机对照试验、标准化评估方法和宿主-微生物组相互作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

npj Biofilms and Microbiomes Immunology and Microbiology-Microbiology

CiteScore

12.10

自引率

3.30%

发文量

审稿时长

9 weeks

期刊介绍： npj Biofilms and Microbiomes is a comprehensive platform that promotes research on biofilms and microbiomes across various scientific disciplines. The journal facilitates cross-disciplinary discussions to enhance our understanding of the biology, ecology, and communal functions of biofilms, populations, and communities. It also focuses on applications in the medical, environmental, and engineering domains. The scope of the journal encompasses all aspects of the field, ranging from cell-cell communication and single cell interactions to the microbiomes of humans, animals, plants, and natural and built environments. The journal also welcomes research on the virome, phageome, mycome, and fungome. It publishes both applied science and theoretical work. As an open access and interdisciplinary journal, its primary goal is to publish significant scientific advancements in microbial biofilms and microbiomes. The journal enables discussions that span multiple disciplines and contributes to our understanding of the social behavior of microbial biofilm populations and communities, and their impact on life, human health, and the environment.